Patent Exclusivity
Legal protection giving a pharmaceutical company exclusive rights to manufacture and sell a drug for a defined period. Patents can cover the molecule, manufacturing process, formulations, uses, and delivery devices. Patent landscapes for peptide drugs are often complex with multiple overlapping patents.
Technical Context
Peptide drug patent strategies are multi-layered: composition of matter patents (the peptide sequence itself — strongest protection, but limited to the 20-year patent term from filing), formulation patents (specific formulations, excipients, concentrations), method of treatment patents (specific indications and dosing regimens), delivery device patents (pen injectors, auto-injectors), manufacturing process patents, and polymorph/salt form patents. Patent term extension (PTE, up to 5 years in the US under the Hatch-Waxman Act) compensates for time lost during regulatory review. For semaglutide, Novo Nordisk holds multiple patents covering the molecule, formulations, manufacturing, delivery devices, and specific uses — creating a patent estate that extends protection beyond the core compound patent. Patent challenges (ANDA Paragraph IV certifications for generics, biosimilar patent dance under BPCIA) are key events in the lifecycle management of peptide drugs.